• 1
    Van Ballegooijen M,van den Akker-van Marle E,Patnick J,Lynge E,Arbyn M,Anttila A,Ronco G,Dik J,Habbema F. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000; 36: 217788.
  • 2
    Peto J,Gilham C,Fletcher O,Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 24956.
  • 3
    Quinn M,Babb P,Jones J,Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999; 318: 9048.
  • 4
    Sigurdsson K. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 1999; 78: 47885.
  • 5
    Koss LG. The papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989; 261: 73743.
  • 6
    Cuzick J,Szarewski A,Terry G,Ho L,Hanby A,Maddox P,Anderson M,Kocjan G,Steele ST,Guillebaud J. Human papillomavirus testing in primary cervical screening. Lancet 1995; 345: 15336.
  • 7
    Raffle AE,Alden B,Mackenzie EF. Detection rates for abnormal cervical smears: what are we screening for? Lancet 1995; 345: 146973.
  • 8
    Bos AB,Rebolj M,Habbema JDF,van Ballegooijen M. Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer 2006; 119: 23725.
  • 9
    Sasieni PD,Cuzick J,Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. Br J Cancer 1996; 73: 10015.
  • 10
    Kinney W,Sung HY,Kearney KA,Miller M,Sawaya G,Hiatt RA. Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer (ICC). Gynecol Oncol 1998; 71: 42830.
  • 11
    Sawaya GF,Grimes DA. New technologies in cervical cytology screening: a word of caution. Obstet Gynecol 1999; 94: 30710.
  • 12
    Dzuba IG,Diaz EY,Allen B,Leonard YF,Lazcano Ponce EC,Shah KV,Bishai D,Lorincz A,Ferris D,Turnbull B,Hernandez Avila AM,Salermon J. The acceptability of self-collected samples for HPV testing vs. the Pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med 2002; 11: 26575.
  • 13
    Dannecker C,Siebert U,Thaler CJ,Kiermeir D,Hepp H,Hillemans P. Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics. Ann Oncol 2004; 15: 8639.
  • 14
    Wright TC,Denny L,Kuhn L,Pollack A,Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000; 283: 816.
  • 15
    Nobbenhuis MA,Helmerhorst TJ,van den Brule AJ,Rozendaal L,Jaspars LH,Voorhorst FJ,Verheijen RH,Meijer CJ. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol 2002; 55: 4359.
  • 16
    Hillemanns P,Kimmig R,Huttemann U,Dannecker C,Thaler CJ. Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. Lancet 1999; 354: 1970.
  • 17
    Kuhn L,Denny L,Pollack A,Lorincz A,Richart RM,Wright TC,Jr. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000; 92: 81825.
  • 18
    Morrison EA,Goldberg GL,Hagan RJ,Kadish AS,Burk RD. Self-administered home cervicovaginal lavage: a novel tool for the clinical-epidemiologic investigation of genital human papillomavirus infections. Am J Obstet Gynecol 1992; 167: 1047.
  • 19
    Harper DM,Noll WW,Belloni DR,Cole BF. Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed-biologic concordance and women's preferences. Am J Obstet Gynecol 2002; 186: 36573.
  • 20
    Brink AA,Meijer CJ,Wiegerinck MA,Nieboer TE,Kruitwagen RF,van Kemenade F,Fransen Daalmeijer N,Hesselink AT,Berkhof J,Snijders PJ. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 2006; 44: 251823.
  • 21
    Walboomers JM,Jacobs MV,Manos MM,Bosch FX,Kummer JA,Shah KV,Snijders PF,Peto J,Meijer CJ,Munoz N. Human papillomavirus is necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 1219.
  • 22
    Cuzick J. Human papillomavirus testing for primary cervical cancer screening. JAMA 2000; 283: 1089.
  • 23
    Bulkmans NW,Rozendaal L,Snijders PJ,Voorhorst FJ,Boeke AJ,Zandwijken GR,van Kemenade FJ,Verheijen RH,van Groningen K,Boon ME,Keuning HJ,van Ballegooijen M et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94101.
  • 24
    Hesselink AT,Bulkmans NWJ,Berkhof J,Lorincz AT,Meijer CJ,Snijders PJ. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol 2006; 44: 36805.
  • 25
    van den Brule AJ,Pol R,Fransen-Dahlmeijer N,Schouls LM,Meijer CJ,Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papilloma virus genotypes. J Clin Microbiol 2002; 40: 77987.
  • 26
    Bulk S,van Kemenade FJ,Rozendaal L,Meijer CJ. The Dutch CISOE-A framework for cytology increases efficacy of screening upon standardization since 1996. J Clin Pathol 2004; 57: 38893.
  • 27
    Berkhof J,de Bruijne MC,Zielinski GD,Bulkmans NW,Rozendaal L,Snijders PJ,Verheijen RH,Meijer CJ. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006; 118: 175968.
  • 28
    van Ballegooijen M,Rebolj M,Meerding WJ,van den Akker-van Marle ME,Berkers LM,Habbema JDF. De Praktijk van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland in 2001. National Evaluation of Cervical Cancer Screening Program in the Netherlands, Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands, 2003.
  • 29
    Bulk S,Visser O,Rozendaal L,Verheijen RH,Meijer CJ. Cervical cancer in the Netherlands 1989–1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 2005; 113: 10059.